{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:27:08Z","timestamp":1782512828917,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R34HL138235"],"award-info":[{"award-number":["R34HL138235"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.chest.2023.01.007","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T02:24:17Z","timestamp":1673576657000},"page":"1144-1155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis"],"prefix":"10.1016","volume":"163","author":[{"given":"Nishant","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis X.","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ingledue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Kopras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"McMahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Swigris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam G.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina K.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.chest.2023.01.007_bib1","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S2213-2600(21)00228-9","article-title":"Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management","volume":"9","author":"McCarthy","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2023.01.007_bib2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1513\/AnnalsATS.202006-702RL","article-title":"Serum vascular endothelial growth factor C as a marker of therapeutic response to sirolimus in lymphangioleiomyomatosis","volume":"18","author":"Gupta","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.chest.2023.01.007_bib3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(13)70090-0","article-title":"Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial","volume":"1","author":"Young","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2023.01.007_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1056\/NEJMc0707517","article-title":"Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis","volume":"358","author":"Young","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2023.01.007_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1378\/chest.10-0573","article-title":"Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases","volume":"138","author":"Young","year":"2010","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2023.01.007_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02066-2018","article-title":"Analysis of the MILES cohort reveals\u00a0determinants of disease progression and treatment response in lymphangioleiomyomatosis","volume":"53","author":"Gupta","year":"2019","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.chest.2023.01.007_bib7","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2023.01.007_bib8","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1164\/rccm.201607-1384ST","article-title":"Official American Thoracic Society\/Japanese Respiratory Society\u00a0clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management","volume":"194","author":"McCormack","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2023.01.007_bib9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4161\/cc.27355","article-title":"Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells","volume":"13","author":"Alayev","year":"2014","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.chest.2023.01.007_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/nyas.12829","article-title":"Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation","volume":"1348","author":"Alayev","year":"2015","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.chest.2023.01.007_bib11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/0008-5472.CAN-09-3537","article-title":"Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62\/SQSTM1 expression and AMPK activation","volume":"70","author":"Puissant","year":"2010","journal-title":"Cancer Res"},{"issue":"47","key":"10.1016\/j.chest.2023.01.007_bib12","doi-asserted-by":"crossref","first-page":"36387","DOI":"10.1074\/jbc.M110.169284","article-title":"Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR","volume":"285","author":"Liu","year":"2010","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.chest.2023.01.007_bib13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1165\/rcmb.2015-0022OC","article-title":"Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors","volume":"53","author":"Alayev","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"10","key":"10.1016\/j.chest.2023.01.007_bib14","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1164\/rccm.201709-1965ST","article-title":"Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society\/Japanese Respiratory Society clinical practice guideline","volume":"196","author":"Gupta","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.chest.2023.01.007_bib15","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.chest.2023.01.007_bib16","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201710-1981ST","article-title":"Recommendations for a standardized pulmonary function report. An official American Thoracic Society technical statement","volume":"196","author":"Culver","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2023.01.007_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02370-2019","article-title":"Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial","volume":"55","author":"El-Chemaly","year":"2020","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.chest.2023.01.007_bib18","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1164\/rccm.201912-2445OC","article-title":"Single-cell transcriptomic analysis identifies a unique pulmonary lymphangioleiomyomatosis cell","volume":"202","author":"Guo","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.chest.2023.01.007_bib19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1513\/AnnalsATS.201610-824OC","article-title":"A\u00a0phase II clinical trial of an aromatase inhibitor for postmenopausal women with lymphangioleiomyomatosis","volume":"14","author":"Lu","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.chest.2023.01.007_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.105898","article-title":"A\u00a0phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex","volume":"163","author":"Krymskaya","year":"2020","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.chest.2023.01.007_bib21","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2017.01.033","article-title":"Sirolimus and autophagy inhibition in lymphangioleiomyomatosis: results of a phase I clinical trial","volume":"151","author":"El-Chemaly","year":"2017","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2023.01.007_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1081\/COPD-200050655","article-title":"Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg scale, and visual analog scale","volume":"2","author":"Ries","year":"2005","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.chest.2023.01.007_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George\u2019s Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"issue":"6","key":"10.1016\/j.chest.2023.01.007_bib24","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1378\/chest.12-0161","article-title":"St. George\u2019s Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis","volume":"143","author":"Swigris","year":"2013","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2023.01.007_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1378\/chest.113.3.619","article-title":"Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego","volume":"113","author":"Eakin","year":"1998","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2023.01.007_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200409-1298OC","article-title":"The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment","volume":"173","author":"Ryu","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.chest.2023.01.007_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mnfr.201200589","article-title":"Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans","volume":"58","author":"Cottart","year":"2014","journal-title":"Mol Nutr Food Res"},{"issue":"22","key":"10.1016\/j.chest.2023.01.007_bib28","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1158\/0008-5472.CAN-10-2364","article-title":"Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis","volume":"70","author":"Brown","year":"2010","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.chest.2023.01.007_bib29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/11531820-000000000-00000","article-title":"Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000\u00a0mg twice daily with food, quercetin and alcohol (ethanol) in healthy human participants","volume":"49","author":"la Porte","year":"2010","journal-title":"Clin Pharmacokinet"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223000417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369223000417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:49:06Z","timestamp":1757926146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369223000417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0012369223000417"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2023.01.007","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2023.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}